Walgreens Boots Alliance (WBA) Earning Somewhat Positive Media Coverage, Accern Reports
Headlines about Walgreens Boots Alliance (NASDAQ:WBA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Walgreens Boots Alliance earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news coverage about the pharmacy operator an impact score of 46.5522477575009 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Walgreens Boots Alliance, Inc. (WBA) Stake Reduced by Neuburgh Advisers LLC – Newburgh Gazette (newburghgazette.com)
- Walgreens Boots Alliance, Inc. (WBA) noted a price change of 0.30% and Commerce Bancshares, Inc. (CBSH) closes … – Stocks Gallery (stocksgallery.com)
- Bollard Group LLC Buys A Little More Walgreens Boots Alliance, Inc. (WBA) Stock In The Last Quarter (highlightpress.com)
- Edited Transcript of WBA earnings conference call or presentation 29-Jun-17 12:30pm GMT (finance.yahoo.com)
Shares of Walgreens Boots Alliance (NASDAQ:WBA) opened at 79.60 on Tuesday. The firm’s 50-day moving average price is $79.15 and its 200 day moving average price is $82.56. The stock has a market cap of $85.18 billion, a P/E ratio of 20.10 and a beta of 1.26. Walgreens Boots Alliance has a 1-year low of $75.18 and a 1-year high of $88.00.
Walgreens Boots Alliance (NASDAQ:WBA) last posted its earnings results on Thursday, June 29th. The pharmacy operator reported $1.33 EPS for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.03. Walgreens Boots Alliance had a return on equity of 17.34% and a net margin of 3.69%. The business had revenue of $30.12 billion for the quarter, compared to analysts’ expectations of $29.72 billion. During the same quarter in the previous year, the firm earned $1.18 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. On average, equities analysts expect that Walgreens Boots Alliance will post $5.01 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 18th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.01%. This is a boost from Walgreens Boots Alliance’s previous quarterly dividend of $0.38. Walgreens Boots Alliance’s payout ratio is 37.78%.
Walgreens Boots Alliance declared that its Board of Directors has initiated a stock buyback plan on Wednesday, April 5th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the pharmacy operator to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.
Several research firms have recently commented on WBA. Needham & Company LLC began coverage on Walgreens Boots Alliance in a research report on Tuesday, June 27th. They issued a “hold” rating for the company. BidaskClub lowered Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 24th. Jefferies Group LLC reissued a “buy” rating and issued a $95.00 price target on shares of Walgreens Boots Alliance in a research report on Friday, March 31st. Leerink Swann set a $86.00 price target on Walgreens Boots Alliance and gave the stock a “buy” rating in a research report on Friday, July 7th. Finally, Credit Suisse Group reissued a “buy” rating and issued a $97.00 price target on shares of Walgreens Boots Alliance in a research report on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $90.69.
In related news, Director William C. Foote sold 2,736 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $85.89, for a total value of $234,995.04. Following the transaction, the director now owns 21,887 shares in the company, valued at approximately $1,879,874.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 13.50% of the company’s stock.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Stock Ratings for Walgreens Boots Alliance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance Inc. and related stocks with our FREE daily email newsletter.